HUITAI Biomedicine Co., Ltd., located in the dynamic city of Chengdu in southwestern China, is a clinical-stage biotechnology company. Our vision is to lead the way in developing innovative treatments for fibrotic diseases, leveraging the safety and efficacy of small peptide therapeutics.
Currently, we are developing a groundbreaking new drug aimed at treating Idiopathic Pulmonary Fibrosis (IPF) by targeting the activation of TGF-β1. Notably, there are no comparable competitors globally. This drug has successfully completed Phase I clinical trials in Beijing, China. We are now preparing to submit a first-in-class new drug clinical trial application to the FDA.
